Who
Heinrich Dreismann
Director
Company insider
Files Form 4 as: Director, Myriad Genetics; Director, Mainz Biomed; Director, Talis Biomedical; Director, Ignyta; Director, Interpace Biosciences; Director, Nanogen.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $286K
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 27 Oct 2006
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —59,701 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —59,701 at $0.00 | filing |
| 13 Feb 2026filed 19 Feb 2026 | Mainz BiomedBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 13 Feb 2026filed 19 Feb 2026 | QUCY Quantum CyberBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —49,796 at $0.00 | filing |
| 9 Sep 2024filed 9 Sep 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Sold | $271K10,000 at $27.05 | filing |
| 6 Jun 2024filed 7 Jun 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —15,695 at $0.00 | filing |
| 9 Jun 2023filed 12 Jun 2023 | Talis Biomedicaloption or derivative | SEC FORM 4 Code A | —5,466 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —15,151 at $0.00 | filing |
| 19 May 2023filed 23 May 2023 | Talis Biomedicaloption or derivative | SEC FORM 4 Code A | —190,000 at $0.00 | filing |
| 2 Jun 2022filed 3 Jun 2022 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —17,275 at $0.00 | filing |
| 8 Feb 2018filed 12 Feb 2018 | Ignytaoption or derivative | SEC FORM 4 Code D | —6,666 at $0.00 | filing |
| 8 Feb 2018filed 12 Feb 2018 | Ignytaoption or derivative | SEC FORM 4 Code D | —10,000 at $0.00 | filing |
| 8 Feb 2018filed 12 Feb 2018 | Ignytaoption or derivative | SEC FORM 4 Code D | —24,000 at $0.00 | filing |
| 8 Feb 2018filed 12 Feb 2018 | Ignytaoption or derivative | SEC FORM 4 Code D | —15,000 at $0.00 | filing |
| 8 Feb 2018filed 12 Feb 2018 | Ignytaoption or derivative | SEC FORM 4 Code D | —15,000 at $0.00 | filing |
| 8 Feb 2018filed 12 Feb 2018 | Ignytaoption or derivative | SEC FORM 4 Code D | —20,000 at $0.00 | filing |
| 13 Jun 2017filed 19 Jun 2017 | Ignytaoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 13 Jun 2016filed 15 Jun 2016 | Ignytaoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 10 Mar 2016filed 11 Mar 2016 | Ignytaoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)MYGN · tickerreport.com · 20 Oct 2026Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing BusinessMYGN · investorideas.com · 20 Oct 2026FinancialContent - Myriad Genetics (MYGN) Stock Trades Up, Here Is WhyMYGN · financialcontent.com · 20 Oct 2026
0 headlines in the last 90 days name Heinrich Dreismann; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.